Analytical Data
-
Gene name
sbi
- Application
-
Species
Staphylococcus aureus
-
Source
E. coli
-
Tag
N- MBP & C- His-Avi
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q2FVK5
-
Expression Region
30-436aa
-
Molecular Weight
94.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SBI, or Secreted Bacterial Immunogenic protein, has garnered significant attention in the field of biochemistry and immunology due to its potential applications in vaccine development and disease treatment. This protein is derived from specific bacterial strains and plays a crucial role in eliciting immune responses in host organisms. Research on SBI is driven by the increasing need for innovative therapeutic strategies to combat infectious diseases and enhance vaccine efficacy. The unique structure and immunogenic properties of SBI make it an attractive candidate for modification and optimization in recombinant proteins, enabling scientists to harness its capabilities for diagnostic and therapeutic purposes. Moreover, advancements in genetic engineering and protein expression technologies have facilitated the production of SBI in various host systems, paving the way for extensive studies on its mechanism of action, stability, and interaction with immune cells. As global health challenges continue to evolve, understanding the fundamental properties and potential applications of SBI through systematic research could lead to breakthroughs in both preventive and therapeutic measures against a plethora of pathogens. This research not only illuminates the underlying biology of SBI but also opens avenues for its practical applications in public health initiatives aimed at improving vaccine formulations and developing novel immunotherapeutics.
